Objective: Evaluation of the efficacy of a patented, compound herbal preparation (CHP) in improving attention, cognition, and impulse control in children with ADHD. Method: Design: A randomized, double-blind, placebo-controlled trial. Setting: University-affiliated tertiary medical center. Participants: 120 children newly diagnosed with ADHD, meeting DSM-IV criteria. Intervention: Random assignment to the herbal treatment group (n = 80) or control group (placebo; n = 40); 73 patients in the treatment group (91%) and 19 in the control group (48%) completed the 4-month trial. Outcome measure: Test of Variables of Attention (TOVA) administered before and after the treatment period; overall score and 4 subscales. Results: The treatment group showed substantial, statistically significant improvement in the 4 subscales and overall TOVA scores, compared with no improvement in the control group, which persisted in an intention-to-treat analysis. Conclusions: The well-tolerated CHP demonstrated improved attention, cognition, and impulse control in the intervention group, indicating promise for ADHD treatment in children.
Background
An estimated 4.4 million school-age children (ages: 3-17) in the United States are reported to have a history of ADHD diagnosis (Bloom & Cohen, 2006; National Center for Health Statistics, 2007) ; of these, more than 2.5 million (over 56%) are reported to be taking medication for the disorder (Centers for Disease Control and Prevention, 2003; Froehlich et al., 2007) .
Recent neurobiological studies have indicated that alterations in catecholaminergic transmitter functions (mainly dopaminergic and noradrenergic), dysfunction of the reticular activating system, and diminished perfusion and cortical activity are related to ADHD symptoms (Hunt, Mandl, Lau, & Hughes, 1991; Kaplan & Sadock, 1995; Volkow et al., 1998; Zametkin & Liotta, 1998) .
Additionally, the ADHD brain may be lacking in neural density. The right hemisphere of the ADHD brain appears on functional magnetic resonance imaging to be, on average, 5% smaller than that of control groups, including a smaller right anterior frontal cortex and less white matter in the right frontal lobe, which can impair sustained or focused attention. Children with ADHD exhibit global cortical thinning, predominantly in prefrontal regions, associated with attentional mechanisms (Bunge, Dudukovic, Thomason, Vaidya, & Gabrieli, 2002; Castellanos et al., 2002; Shaw et al., 2006; Swanson & Castellanos, 2002; Vaidya et al., 2005) .
Psychostimulants have been proven effective in shortterm controlled studies for reducing ADHD symptoms and are prescribed frequently (American Psychiatric Association, 2000; Chatfield, 2002) . However, for individuals with counterindications to current drug therapies, there are few alternatives available that have demonstrated comparable effectiveness.
Additionally, controversy over long-term safety concerns surrounding drug therapies may contribute to noncompliance, or even failure, to seek treatment altogether (Charach, Figueroa, Chen, Ickowicz, & Schachar, 2006; Charach, Ickowicz, & Schachar, 2004; Jensen et al., 2007; Poulton, 2005; Scarnati, 1986; Spencer et al., 2006; Vitiello, 2008; Zachor, Roberts, Hodgens, Isaacs, & Merrick, 2006) . Alternate, safe, and well-tolerated ADHD interventions, which demonstrate efficacy in improving functional parameters of ADHD and can potentially broaden therapeutic options available to patients and clinicians, warrant study and consideration. For this purpose, we designed a randomized, double-blind, placebo-controlled clinical trial of a compound herbal preparation (referred to henceforth as "CHP") for the treatment of ADHD. The CHP formula, a patented blend of nutritive, food-grade herbs called Nurture & Clarity, was designed by a team of Israeli herbalists (authors Levine, Kol-Degani, & Kav-Venaki), based on extensive clinical experience in treating children with ADHD, utilizing traditional Chinese medicine (TCM) protocols.
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The herbs in the CHP, some considered legendary for centuries for their cognition-enhancing properties in various herbal medicine traditions, seem to demonstrate enhancement of several brain, neurological, and performance parameters as shown by a growing body of research concerning ADHD (Bensky & Gamble, 1993; Blumenthal, 1998; Brinkhaus, Lindner, Schuppan, & Hahn, 2000; Carlini, 2003; Ciferri & Tiboni, 1985; Hostettmann, Marston, Maillard, & Hamburger, 1995; Keys, 1976; Otles & Pire, 2001; Tohda et al., 2005) .
Therapeutic mechanisms of the CHP herbal ingredients that enhance cognition, attention, and impulse control appear to involve enhancement of catecholaminergic transmitter functions (Wake et al., 2000) , acetylcholinesterase (AChE) inhibitory activity Vinutha et al., 2007) , noradrenaline-releasing action (Liu et al., 2002) , stimulation of growth of axons and dendrites in human neuroblastoma cells Tohda, Kuboyama, & Komatsu, 2000; Zhao et al., 2002) , enhancement of cerebral oxygenation (Liu, Lin, Xian, & Zhu, 2006) , GABA mimetic activity (Mehta, Binkley, Gandhi, & Ticku, 1991) , and nutritive and antioxidant effects (Bhattacharya, Satyan, & Ghosal, 1997; Paladini et al., 1999 ) (see appendix).
Pediatric psychopharmacology involves a developing neurobiology. Pediatric brain maturation is characterized by complex, ongoing molecular, anatomic, and organizational changes. Prolific trophic nerve growth factors in the developing nervous system, neurons, cell processes, and neurotransmitters are critical to rapid neural network formation, growth, and development.
Increasing research indicates that this prolific growth in the developing nervous system requires adequate external intake of crucial essential nutrients, through diet or supplementation, to avoid possible compromise to optimal brain growth and development (Baynes & Dominiczak, 1999; Harding, Judah, & Gant, 2003; Makrides, Neumann, Simmer, Pater, & Gibson, 1995; Schnoll, Burshteyn, & Cea-Aravena, 2003; Stevenson, 2006) .
Increasing evidence suggests that these nutritional deficiencies are common in ADHD and may even exacerbate any already existing pathology, regardless of original specific etiology (Harding et al., 2003; Kidd, 1999 Kidd, , 2000 Schnoll et al., 2003; Sinn, 2007; Stevenson, 2006; Wurtman, 1988; Zimmer et al., 2002) .
The CHP herbal ingredients supply these essential nutrients, including essential fatty acids, phospholipids, essential amino acids, B-vitamins, minerals, and other micronutrients needed for normal brain growth and development (Brinkhaus et al., 2000; Ciferri & Tiboni, 1985; Otles & Pire, 2001) . Preliminary evidence supports the idea that supplementation with these nutrients may help to ameliorate ADHD symptoms, regardless of etiology (Benton & Roberts, 1998; Bornstein et al., 1990; Coleman et al., 1979; Dean, Morgenthaler, & Fowkes, 1993; Hodge et al., 2007; Kozielec & Starobrat-Hermelin, 1997; Lozoff, 1989; Sinn & Bryan, 2007; Toren, Eldar, & Sela, 1996) .
The CHP formula under study was hypothesized to improve cognition, attention, and impulse control in the treatment group, as compared with the control group. The study was approved by the Sheba Medical Center Ethical Review Board, in compliance with the Helsinki declaration, and by the Israeli Ministry of Health. The Israeli Ministry of Health approved the CHP herbal ingredients as safe, food-grade botanicals.
Trial registration: Current Controlled Trials ISRCTN-10628149.
Method Participants
A total 120 children, aged 6-12 years, participated in this study (see Table 1 ). All participants were recruited at the Sheba Medical Center (one of the largest universityaffiliated tertiary care centers in Israel) Pediatric ADHD and Adaptation Clinic. None had a history of prior treatment for ADHD. Patients were diagnosed with ADHD (all types) by a specialized pediatric psychiatrist (author Katz), based on Diagnostic and Statistical Manual of Mental Disorders (4th ed.; DSM-IV) criteria and assessment interviews with participants and their parents. The clinical trial was performed using a 2:1 assignment ratio for the treatment group (n = 80) and a control group (n = 40). Participants were given the CHP formula or placebo. In light of the authors' prior positive clinical experience with this CHP, the 2:1 assignment ratio was designed to minimize the number of untreated controls, yet still provide adequate statistical power (77%) to detect an improvement in test of variables of attention (TOVA) scores in the intervention versus the control group, in the order of one half of a standard deviation of the baseline scores.
During the course of the clinical trial, the participants were treated only with the CHP or placebo. Parents were given full explanations and signed informed consent forms. Verbal agreement to participate in the study was obtained from the children.
The Compound Herbal Preparation (CHP)
The CHP being evaluated consisted of a patented blend of nutritive, food-grade herbs, prepared as a highly stable, dilute ethanol extract called Nurture & Clarity. The primary active herbal ingredients of the CHP include Paeoniae Alba, Withania Somnifera , Centella Asiatica, Spirulina Platensis, Bacopa Monieri, and Mellissa Officinalis (see appendix).
The raw herbs, purchased from MayWay Co. Ltd. (Auckland, California), and a local supplier, were examined and certified as free of bacteria, fungus, and heavy metals and were approved by the Israeli Ministry of Health as safe, food-grade herbs. Standardization was ensured utilizing TLC (thin layer chromatography). The herbal formulation was prepared by the pharmacy laboratory of the Tree of Healing-LD Clinic, Herzliya, Israel.
The placebo preparation was prepared by a pharmaceutical contractor and was designed to taste, smell, and look similar to the herbal formula. The CHP and placebo formulations were supplied in identical glass containers. When evaluated by 20 medical students, they were unable to distinguish it from the CHP. A dose of 3 ml of the CHP or placebo was taken by the participants 3 times daily, before meals, diluted in 50 to 60 ml of water.
Pretreatment Screening and Baseline Assessment
None of the participants had received any form of treatment for ADHD prior to the clinical trial. Children, 6-12 years of age, who met DSM-IV criteria for ADHD (all types; American Psychiatric Association, 2000), as assessed utilizing a structured diagnostic interview by a specialized pediatric psychiatrist (author Katz), were eligible to participate.
All patients were required to meet a symptom severity threshold: a score of at least 1.5 standard deviations above age and gender norms, as assessed by the pediatric psychiatristadministered and -scored parent version of the ADHD Rating Scale-IV, and a CGI Severity ADHD Rating greater than or equal to 4 (DuPaul, Power, Anastopoulos, & Reid, 1998; Faries, Yalcin, Harder, & Heiligenstein, 2001) . Other assessments included the Conners' Parent Rating ScaleRevised: Short Form (Conners, Sitarenios, Parker, & Epstein, 1998a) , and the Conners' Teacher Rating Scale-Revised: Short Form (Conners et al., 1998b ). Confirmation that the child's ADHD symptoms interfered with classroom performance was obtained from a review of the ADHD Rating Scale completed by the teacher, as well as through telephone contact with the teacher.
Comorbid psychiatric conditions were assessed clinically by the specialized pediatric psychiatrist (author Katz), who conducted joint parent and child clinical interviews to screen for anxiety, depression, bipolar disorder, psychosis, or other comorbid conditions, and confirmed by the Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL; Kaufman, Birmaher, Brent, Rao, & Ryan, 1996) .
The screening included a medical history and a physical examination. Routine clinical laboratory tests and electrocardiogram were performed at the screening visit and at the trial end point. Exclusion criteria included all identified medical conditions or illnesses (such as anemia, hypoglycemia, thyroid disorders, etc.), psychiatric comorbid conditions, or ongoing use of any medications.
Following a clinical evaluation of each participant, children meeting the DSM-IV criteria for inclusion in the study were evaluated with the TOVA (Leark, Dupuy, Greenberg, Corman, & Kindschi, 1996) , establishing an objective baseline for performance of tasks. Study inclusion required a standard score of below 85 on at least one of the TOVA subscales: omission, commission, response rate, or variability. The TOVA requires tracking of visual stimuli with differential response/nonresponse to target and nontarget stimuli, measuring deviations of inattention, impulsivity, response rate, and consistency (Leark et al., 1996) . The trial evaluated each parameter separately as well as an overall score.
Trial Procedure
A randomized, double-blind, placebo-controlled trial was conducted over a 4-month period. Participants were randomly assigned, using a table of random numbers, to one of two groups: the treatment group (n = 80), or the control group (n = 40). Randomization was performed by a research assistant, who was distant from the intervention; had no contact with participants; was the only member of the team responsible for dispensing the appropriate formula for each participant-in identical glass bottles, labeled by name; and had no further involvement in the trial. Distribution to participants was then carried out by a blinded team member, according to the name on the label. Participants
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were to receive either the CHP or a placebo, according to their random allocation.
The CHP or placebo was home administered by parents throughout the study. The identical glass bottles, labeled by patients' names, were dispensed to the parents at the regular individual meetings, at 3-to 4-week intervals. Compliance record forms, which were to be checked off and signed after each dose administration, were collected at each meeting. Parents were instructed how to prepare (dilute in water) the daily dosage for the entire day. The morning, afternoon, and evening doses were administered at home before breakfast, lunch, and dinner. Alternatively, the noon/afternoon dose was taken at school, administered by an assigned teacher, who then checked off and signed the compliance record form.
Additionally, a detailed parent-rated, daily questionnaire diary was developed for this study, which included possible adverse events, such as insomnia, abdominal pains, nightmares, anxiety, rashes, dizziness, appetite loss, and so on. Clinical assessment interviews to detect side effects were conducted 3 times during the trial period by the pediatric psychiatrist (author Katz), who was blinded as to the treatment allocation. Figure 1 displays the flow diagram of study participants from randomization to trial completion. During the course of the trial (following randomization and coded bottle distribution), 4 participants withdrew from the intervention group and 18 from the control group. A further 6 participants, who completed the trial but had not submitted their baseline TOVA tests-3 in each group, were excluded from the main analysis, leaving 73 of those allocated to treatment (91%) and 19 of those allocated to placebo (48%), with full data. The inequality in withdrawals is unlikely to be due to chance (p < .0001). The reasons parents cited for dropout were (a) parental unwillingness to continue treatment in the absence of immediate improvement (2 = placebo, 0 = treatment); (b) parent perceived school pressure to begin drug treatment in cases of disruptive behavior and in the absence of immediate improvement (4 = placebo, 1 = treatment); (c) failure or inability of parents or children to comply with daily dosage administration (6 = placebo, 2 = treatment); (d) contraction of routine minor illness by participant, including throat infection, which required antibiotic treatment (1 = placebo, 0 = treatment); (e) common cold or other minor condition in which the participant discontinued daily dosage administration for more than 1 week (1 = placebo, 1 = treatment); (f) objection to CHP taste, as not sufficiently pleasant (1 = placebo, 0 = treatment); (g) family moved from area (1 = placebo, 0 = treatment); and (h) unknown (2 = placebo, 0 = treatment). Double masking of treatment status was strictly maintained by the study team. Parents, children, and the investigators remained blinded to treatment status until completion of the trial.
Posttreatment Assessment
Upon completion of the 4-month trial period, each patient was reevaluated using the TOVA, which was administered by a psychology student blinded as to treatment status.
Safety Analyses
The trial was monitored for safety and tolerability by way of individual meetings at 3-to 4-week intervals, in which adverse events were systematically assessed by the primary clinician (authors Kol-Degani or Kav-Venaki) via openended discussion with each participant and their parents, as well as by regular monitoring of weight and vital signs, including heart rate and blood pressure. Additionally, the pediatric psychiatrist (author Katz) conducted clinical assessment interviews with each participant and his or her parents 3 times during the trial period.
No serious adverse events were reported, and the rate of even mild adverse events among CHP-treated patients was actually less than that of placebo. All complaints were mild, transient, and did not persist past the first 2 weeks of treatment. Complaints included the following:
Gastrointestinal discomfort: Placebo group (n = 3) and treatment group (n = 2), Nausea: Placebo group (n = 2) and treatment group (n = 2), Headache: Placebo group (n = 1) and treatment group (n = 2), Decreased appetite: Placebo group (n = 2) and treatment group (n = 1), Sleep disturbance: Placebo group (n = 4) and treatment group (n = 1), Vomiting: Placebo group (n = 2) and treatment group (n = 0), Sedation: Placebo group (n = 1) and treatment group (n = 1), Emotional lability: Placebo group (n = 4) and treatment group (n = 2), and Accidental injury: Placebo group (n = 2) and treatment group (n = 1).
None of the adverse events were more frequent in the CHP group than in the placebo group. There were no significant alterations in clinical laboratory test results. There were no significant changes in weight from baseline to endpoint in either group that differed from normal growth chart rates, with no significant differences between groups.
Statistical Method
The data were analyzed using SPSS software, version 14 (SPSS Inc. Chicago, IL, USA). Fisher's exact test was used to assess the differences in categorical variables between comparison groups; t tests were applied to appraise differences in interval or continuous variables, such as the 4 TOVA subscales. Paired t tests were used to test within-subject change from baseline to completion of the trial. There was no material difference in response among the different ADHD types (ADHD-PI, ADHD-HI, and ADHD-C); consequently, they were pooled in the analysis. As the TOVA scores were not normally distributed (although reasonably so), we also undertook a nonparametric analysis using the MannWhitney U test, to assess the difference between the experimental groups for the change in TOVA scores, from baseline to the end of the trial.
The findings were entirely consistent with the one-way ANOVA. We next adjusted for the baseline scores of each of the 4 subscales, and the overall TOVA score by GLM ANOVA, and then added age and sex as covariates in multivariable models, to appraise the treatment effect independently of between-group differences in baseline TOVA scores, age, and sex. In addition, we undertook a conservative intention-to-treat analysis. For the 21 children in the placebo group who did not complete the trial, we allocated overall TOVA scores that reflected the mean improvement in TOVA of the 73 children in the treatment group who completed the trial and for the 7 children in the treatment group who did not complete the trial, we allocated TOVA scores that reflected no improvement during the trial.
Results
Characteristics of those allocated to treatment or placebo were similar with respect to gender (78% and 83% boys, respectively; p = .64). The intervention group was slightly older (9.72 + 1.58 vs. 9.20 + 1.82, p = .11) but resembled the control group in regard to the baseline TOVA scores (85.8 ± 12.1 vs. 87.8 ± 12.6, p = .53, for the composite TOVA score). The treatment and placebo groups that completed the trial (n = 73 and n = 19, respectively) were similar in regards to age, gender, and the baseline TOVA subscales, and overall score (Table 1 ). There were no significant differences in sex, age, or baseline TOVA scores between control group participants who withdrew and those who persisted, 86.7 ± 13.2 (n = 18) vs. 88.7 ± 12.3 (n = 19), p = .63, for the baseline overall TOVA score.
In the treatment group, there was a highly significant improvement (p < .0001) in all 4 dimensions of the TOVA, as well as for the overall score, in contrast with the control group in which there was no significant difference in all the measures during the 4-month trial period (Table 2) . A comparison of the before and after differences between the treatment and placebo groups showed that these were largest for the response time and variability subscales, substantially exceeding a full standard deviation of the baseline values in magnitude but statistically significant for the other two dimensions, as well as for the overall score, for which the difference was considerable. We controlled for the baseline values of each of the subscales by ANOVA; the findings persisted largely undiminished: treatment effect (i.e., before vs. after difference between intervention and control group scores) for omission: 15.5 (95% CI 6.5-24.5), commission: 8.0 (95% CI 1.9-14.1), response time: 15.4 (95% CI 7.4-23.5), variability: 20.2 (95% CI 10.4-29.9), and overall TOVA: 14.9 (95% CI 8.9-20.8). In a nonparametric analysis (Mann-Whitney U test; Table 3 ), we compared the median change in TOVA scores from the baseline values to completion of the trial between the treatment and placebo groups. The findings were entirely consistent with the previous analysis, being statistically significant for all dimensions of the TOVA, but strongest for variability, response time, and the overall score. Next, using multivariable GLM ANOVA, we assessed treatment differences for each of the 4 subscales and for the overall TOVA score adjusting for age, sex, and baseline TOVA score, to control for (nonsignificant) between-group inequalities in baseline characteristics (Table 4 ). The adjusted mean treatment effect for the overall TOVA score (14.8, SE = 3.0, p < .0001) was only slightly attenuated from the unadjusted difference (16.8, SE = 3.5). Findings for each of the 4 subscales persisted strongly. The proportion of the variance in the before versus after differences attributable to treatment group was 13.5% for omission, 7% for commission, 13.6% for response time, 16.1% for variability, and 21.9% for the full TOVA score. Finally, in a conservative intention-to-treat analysis, we included all 120 participants: 80 in the treatment group and 40 in the controls (see Methods). The treatment effect remained statistically significant (p =.004 when controlled for the baseline TOVA, and p = .004 for the multivariable model). 
Discussion
Individuals with ADHD can experience long-term chronic difficulties, often resulting in significant academic, behavioral, psychological, and social problems. A safe, well-tolerated ADHD intervention, with demonstrated efficacy in improving functional parameters of ADHD, which can offer an alternative to current drug therapy, warrants consideration and further investigation. This study demonstrates that treatment with the CHP over a 4-month period led to improvement in all dimensions of the TOVA, which was strongest for variability, response time, and for the overall score, an improvement that was absent in the control group. This treatment effect persisted on adjustment for age, sex, and baseline TOVA values.
At termination of the trial, all children who participated in the trial were eligible for treatment with the CHP for 6 months, and those who chose this continued to be subject to regular monthly assessment monitoring, as before, with similar tolerability.
Limitations
A limitation of our trial is the differential loss to follow-up in the treatment and placebo groups, leaving 73 of the initial 80 in the treatment group and only 19 of the initial 40 in the control group for analysis. Although masking of treatment status was scrupulously maintained by the study team, the highly significant difference in the rates of completion in both trial groups (p < .0001) suggests that patients (or their surroundings) may have perceived their lack of improvement (largely in the control group) and may have guessed their treatment status. The high withdrawal rate revealed in the control group on completion of the trial, additionally, exacerbated the initial designed inequality between both trial groups. The investigators structured the study with a 2:1 assignment ratio (80 in the treatment group and 40 in the control group), in order to limit the number of untreated controls (under the assumption of a positive treatment effect), yet still provide adequate power.
Such unequal withdrawal can potentially lead to selection bias. The fact that the treatment and control groups that completed the trial were similar in their baseline characteristics partly alleviates this concern. Furthermore, we assume that parents of children in the control group who showed improvement would be unlikely to withdraw them from the trial. It would seem more likely that these withdrawn children would have similar or worse TOVA change scores than the control children who persisted in the trial. The supposition is supported by an analysis of the main reasons given for withdrawal-6 children of the placebo versus 1 of the treatment group withdrew because they noted no immediate improvement or due to school pressure to commence therapy (and opted for conventional drugs, which suggests no improvement), and 6 children in the placebo group versus 2 in the treatment group withdrew because they were unable to comply with the treatment regime (plus another child who did not like the taste of the placebo), which suggests a lack of motivation to continue (also indicative of no rewarding improvement).
Furthermore, significant differences between the trial groups persisted in an intention-to-treat analysis, which assumed that the children withdrawn from the placebo group experienced an improvement in their TOVA scores equal to the average improvement of the intervention group and that children withdrawn from the treatment group had no improvement. Therefore, we conclude that although unequal withdrawal remains a concern in interpreting the results of our trial, we consider that it was unlikely to produce the treatment effect noted. The compound herbal preparations (CHP/ CHP-H) under study (registered by Tree of Healing-LD Clinic under the name "Rikuzit" in Israel, and "Nurture & Clarity" internationally) are at this time only available to Tree of Healing-LD Clinic patients undergoing therapy. The CHP has, until now, been produced in-house, using simple ethanol extraction in the pharmacy laboratory of the Tree of Healing-LD Clinic, in quantities sufficient to supply patients undergoing therapy. At this time, therefore, the CHP is not connected with any pharmaceutical or manufacturing company.
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